for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Albireo Pharma Inc

ALBO.OQ

Latest Trade

17.61USD

Change

0.00(0.00%)

Volume

14,372

Today's Range

17.28

 - 

18.05

52 Week Range

16.26

 - 

38.48

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
17.61
Open
17.74
Volume
14,372
3M AVG Volume
1.13
Today's High
18.05
Today's Low
17.28
52 Week High
38.48
52 Week Low
16.26
Shares Out (MIL)
12.69
Market Cap (MIL)
223.39
Forward P/E
-2.95
Dividend (Yield %)
--

Latest Developments

More

Albireo Pharma Q2 Loss Per Share $1.35

Albireo Provides Mid-Year Clinical Development Update

Albireo Pharma Reports Q1 Loss Per Share Of $1.39

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Albireo Pharma Inc

Albireo Pharma, Inc., formerly Biodel Inc., is a specialty biopharmaceutical company. It is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI), disorders where improper flow or absorption of bile causes serious medical conditions for which there is unmet need. The target indication for its lead product candidate, A4250, is progressive familial intrahepatic cholestasis (PFIC), which is a genetic disorder affecting children. A4250 is being evaluated in a Phase II clinical trial. Other products in the Company's pipeline include Elobixibat, A3384 and Bile Acid Modulators. Elobixibat is indicated for the treatment of chronic constipation and it has completed its Phase III clinical trials. A3384 is a formulation of cholestyramine that is designed to release cholestyramine directly in the colon. It has completed a Phase II clinical trial of a prior formulation of A3384 in bile acid malabsorption (BAM).

Industry

Biotechnology & Drugs

Contact Info

10 Post Office Square, Suite 502 South

+1.857.4154774

http://www.albireopharma.com/

Executive Leadership

David Chiswell

Independent Chairman of the Board

Ronald Harold Wilfred Cooper

President, Chief Executive Officer, Director

Simon N.R. Harford

Chief Financial Officer, Treasurer

Jan P. Mattsson

Chief Scientific Officer

Martha J. Carter

Chief Regulatory Officer

Key Stats

1.50 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2017

-3.150

2018

-3.940

2019(E)

-5.921
Price To Earnings (TTM)
--
Price To Sales (TTM)
85.00
Price To Book (MRQ)
1.90
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-34.48
Return on Equity (TTM)
-32.73

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up